Aurobindo Pharma Ltd (Aurobindo) is an international pharmaceutical firm that produces generic formulations, active pharmaceutical ingredients (APIs), and specialty medicines. The company researches, manufactures, and markets a broad range of generics, specialty products and injectables, APIs, and complex platforms including biosimilars, vaccines, peptides, and metered dose inhalers. It serves more than 150 countries and runs over 30 manufacturing and packaging sites. Its portfolio spans seven major therapeutic categories, including antibiotics, antiretrovirals (ARVs), cardiovascular, central nervous system (CNS), anti-diabetics, gastroenterologicals, and anti-infectives. The company organizes operations into five reportable segments: US Formulations, EU Formulations, Growth Markets Formulations, ARV Formulations, and API Business. It also delivers customer-focused project-based chemistry services and stability study work via AuroSource; end-to-end solutions from discovery through development and commercialization to economical drug development and manufacturing through Auro Peptides Ltd; and biocatalysts used in pharmaceutical and chemical industries through AuroZymes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Aurobindo is committed to enhancing patient impact through continuous research and development in pharmaceuticals. The company leverages advanced technologies, strategic partnerships, and a commitment to sustainability to drive excellence in research and development. It employs more than 1,500 scientists and analysts in product development. Key developments in FY2025 include receiving final approvals for numerous US ANDAs from the US FDA and filing of the first transdermal ANDA with a focus on product/process development. The R&D units of Aurobindo Pharma include Aurobindo Research Centre, Eugia Pharma, and Apitoria Pharma. The company has more than 30 state-of-the-art manufacturing and packaging facilities, which are approved by regulatory agencies such as the US FDA, EU GMP, South Africa-MCC, UK MHRA, Health Canada, Brazil ANVISA, and WHO. The company operates nine research facilities. The company has launched 33 products in the US market. As of March 2026, the company filed 888 ANDAs with the US FDA and 322 DMFs. The company has strategic collaborations with AI-based scientific companies and research collaborations focused on advanced informatics. In FY2026, the company spent INR15,900 million on its R&D activities, which as a percentage of revenue stood at 4.7%.